Neuren Pharmaceuticals Limited (AU:NEU) has released an update.
Neuren Pharmaceuticals stands to gain financially as its partner, Acadia Pharmaceuticals, sells a Rare Pediatric Disease Priority Review Voucher for $150 million. Neuren is set to receive one-third of the net proceeds from this transaction, boosting its financial position. This development highlights Neuren’s strategic partnerships in advancing treatments for rare neurological disorders.
For further insights into AU:NEU stock, check out TipRanks’ Stock Analysis page.
